Despite the expiry of the substance patent of the DPP-4 inhibitor diabetes drug Trajenta (linagliptin) set for the 8th of next month, most of its generic versions will not be launched at that time.

Only products with the first generic exclusivity will be released, and the rest will only be allowed sale in March next year after the sales ban period is lifted.

According to industry sources on June 28, a total of 15 generic versions of Trajenta will be listed with reimbursement on June 9. On the day, the following pharmaceutical companies will be launching generic versions of Tragenta: Korea Arlico Pharm, Hutecs Korea Pharmaceutical, Alvogen Korea, Aju Pharmaceutical, Boryung Pharm